Novo Nordisk Expands Legal Campaign Against Compounders of GLP-1 Drugs

Legal Actions:
Novo Nordisk has filed 11 new lawsuits against med spas, weight loss clinics, and telehealth companies advertising compounded versions of GLP-1 drugs, expanding its legal campaign to protect patients from potentially harmful products.

Patient Safety Concerns:
The company is concerned about the safety of compounded drugs claiming to contain semaglutide, which have been associated with serious adverse events, hospitalizations, and deaths.

FDA-Approved Medicines:
Novo Nordisk emphasizes the importance of using FDA-approved semaglutide products, such as Ozempic and Rybelsus, to ensure patient safety and efficacy.

Earnings and Market Impact:
Despite the legal actions, Novo Nordisk's earnings report showed a 25% increase in sales at constant exchange rates, though this was below analyst expectations, leading to a drop in the company's shares.

Competition in Obesity Medicine:
The company faces increasing competition in the obesity medicine market, prompting efforts to increase supplies of its GLP-1 drugs to reach more patients.